PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and Financial Condition.
On May10, 2017, Protagonist Therapeutics, Inc. reported its
financial results for the quarter ended March31, 2017. A copy of
the press release titled Protagonist Therapeutics Reports First
Quarter 2017 Financial Results, is furnished to Item 2.02 as
Exhibit 99.1 hereto and is incorporated herein by reference.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
Description |
|
| 99.1 |
Press release, dated May10, 2017, titled Protagonist Therapeutics Reports First Quarter 2017 Financial Results. |
The information in this report, including the exhibit hereto,
shall not be deemed to be filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained
herein and in the accompanying exhibit shall not be incorporated
by reference into any filing with the U.S. Securities and
Exchange Commission made by Protagonist Therapeutics, Inc.,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
About PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases. PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) Recent Trading Information
PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) closed its last trading session up +0.25 at 9.65 with 20,037 shares trading hands.
